Ratos completes offer to shareholders and convertible debenture holders in Biolin Scientific

2010-12-23

This information is disclosed in accordance with the Securities Markets Act and
   NASDAQ OMX Stockholm's rules regarding public offers on the stock market.

This press release may not be distributed, directly or indirectly, in or into,
Australia, Canada, Japan, New Zealand, South Africa, Switzerland or the United
States of America. The Offer is not being made to (and acceptances will not be
accepted from) persons in those countries or in any other country where the
making of the Offer, the distribution of this press release or acceptance of the
Offer requires further offer documents, filings or other measures in addition to
those required by Swedish law.
Shareholders and convertible debenture holders representing 16 811 845 shares in
Biolin Scientific, corresponding to 63,25%[1] of the capital and votes, have
accepted Ratos's offer. This means that Ratos now, including the shares acquired
by Ratos through the agreements Ratos entered into with Farstorp Invest AB and
Bo Håkansson prior to the announcement of the offer, holds a total of
24 424 074 shares and convertibles in Biolin Scientific, corresponding to
91,89%[1] of the capital and votes. Since all terms and conditions for
completion of the offer have thus been fulfilled, Ratos has decided to complete
the offer. Ratos has also decided to extend the acceptance period until 12
January 2011.
On 29 November 2010, Ratos announced an offer to shareholders and convertible
debenture holders in Biolin Scientific to acquire all shares and convertibles
for a cash payment of SEK 11.50 for each share and each convertible debenture.
The acceptance period for the offer was 1-21 December 2010.
In order to allow participation in the offer for those shareholders and
convertible debenture holders who have not yet accepted the offer, the
acceptance period will be extended until 17.00 CET on 12 January 2011.
For the shareholders and convertible debenture holders in Biolin Scientific who
accepted the offer during the ordinary acceptance period, settlement is expected
to commence on 28 December 2010. For those who accept the offer during the
extended acceptance period, settlement is expected to commence on 19 January
2011. Since the offer is now unconditional, shareholders and convertible
debenture holders who accept the offer will not be entitled to withdraw their
acceptances.
Since Ratos holds more than 90% of the capital and votes in Biolin Scientific,
Ratos intends shortly to initiate compulsory acquisition of the remaining shares
in Biolin Scientific and to promote a delisting of Biolin Scientific's shares
from NASDAQ OMX Stockholm.
[1] Calculated after full dilution.

For further information, please contact:
Arne Karlsson, CEO, through Nina Aggebäck, +46 76 125 09 01
Emma Rheborg, Head of Corporate Communications and IR, +46 733 80 22 63

Financial calendar from Ratos:
Year-end report 2010                       17 February 2011
Annual General Meeting 2011                5 April 2011
Interim Report January - March 2011        5 May 2011
Interim Report January - June 2011         19 August 2011
Interim Report January - September 2011    9 November 2011

Ratos is a private equity conglomerate. The company's mission is to maximise
shareholder value over time through the professional, active and responsible
exercise of its ownership role in primarily medium to large unlisted Nordic
companies. Ratos's holdings include AH Industries, Anticimex, Arcus Gruppen,
Bisnode, Camfil, Contex, DIAB, EuroMaint, GS-Hydro, Hafa Bathroom Group, HL
Display, Inwido, Jøtul, KVD Kvarndammen, Lindab, Medisize, Mobile Climate
Control, SB Seating, Stofa, Superfos and Other holdings. Ratos is listed on
NASDAQ OMX Stockholm and market capitalisation amounts to approximately SEK 40
billion.